Shares of medical device maker Enovis Corporation (ENOV) plummeted 9.46% in pre-market trading on Thursday, following the company's announcement of a reduced profit forecast for 2025, despite reporting better-than-expected first-quarter results. The sharp decline reflects investors' concerns over the impact of tariffs on the company's profitability.
Enovis reported first-quarter adjusted earnings of $0.81 per share, surpassing analysts' estimates of $0.74. The company also raised its 2025 revenue forecast to a range of $2.22 billion to $2.25 billion, up from the prior projection of $2.19 billion to $2.22 billion. However, these positive aspects were overshadowed by the revised profit guidance.
The medical device maker cut its annual profit forecast to a range of $2.95 to $3.10 per share, down from its previous guidance of $3.10 to $3.25. This reduction is primarily attributed to an anticipated $20 million impact related to tariffs. Additionally, Enovis lowered its adjusted EBITDA forecast to $385-395 million from the previous $405-415 million. While CEO Matt Trerotola emphasized the company's strong start to 2025, with first-quarter revenues and margins exceeding expectations, the revised profit guidance has clearly overshadowed these positive aspects in investors' minds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.